At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 186 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib cream and Vehicle for Hand Eczema. Completed, enrolled 186 participants across 36 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHand Eczema
CountriesCanada, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedJun 2023
Enrollment StartJul 2023
Primary CompletionJul 2024
Study CompletionDec 2024
TodayJul 2026
First PostedJun 18, 2023
Enrollment StartJul 31, 2023
Primary CompletionJul 15, 2024
Study CompletionDec 13, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.0 years ago
Interventions
Ruxolitinib creamdrug
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Vehicledrug
Vehicle cream is a topical formulation applied as a thin film to affected areas.